Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume

Published:2023-11-27 Issue:1 Volume:15 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Desai M.¹,Kundu A.²,Hageman M.³,Lou H.⁴,Boisvert D.⁵

Affiliation:

1. Medical Affairs, Enable Injections, Inc, Cincinnati, OH, USA

2. Manufacturing Sciences, Takeda Pharmaceuticals, Brooklyn Park, MN, USA

3. Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, USA

4. Biopharmaceutical Innovation & Optimization Center, The University of Kansas, Lawrence, KS, USA

5. Independent Chemistry Manufacturing & Controls (CMC) Consultant, El Cerrito, CA, USA

Funder

Enable Injections, Inc

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2023.2285277

Reference148 articles.

1. Clinical pharmacology considerations in biologics development

2. Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021

3. The global landscape of approved antibody therapies

4. Fresh from the biotech pipeline: fewer approvals, but biologics gain share

5. Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors;The Oncologist;2024-07-09

2. Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system;Current Medical Research and Opinion;2024-05-17

3. Advancements in Cancer Immunotherapy: Exploring Treatment Options;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3